Lupin signs distribution agreements in key EU territories for orphan drug NaMuscla®

Lupin signs distribution agreements in key EU territories for orphan drug NaMusclaA®Enables expanded patient access of rare disease medicine to treat myotonia symptoms in non-dystrophic myotonic disorders in three key territoriesZug, Switzerland, 3 June: Lupin is pleased to announce that it has entered into distribution agreements with three companies for its orphan drug NaMusclaA® (mexiletine). Exeltis Healthcare S.L, Cresco Pharma B.V and Macure Pharma ApS will commercialize NaMusculaA® for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders in certain EU territories. NaMusculaA® is the first and only licensed product for this indication.NDM disorders are a group of rare, inherited neuromuscular disorders which cause the inability to relax muscles following voluntary contraction. NaMusclaA® reduces myotonia symptoms in adult patients, resulting in a significant improvement in patient quality-of-life and other functional and clinical outcomes1. NaMusclaA®, which has been designated orphan drug status, received EU marketing authorization in December 2018.Under the agreements announced today, Exeltis Healthcare S.L will commercialize NaMusclaA® in Spain and Portugal, Cresco Pharma B.V will commercialize NaMusclaA® in the Netherlands and Macure Pharma ApS in the Nordic countries. Lupin will continue commercialization of NaMuscula A® in Germany and UK and will launch the product in Austria and France later this year.
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Январь 2022    »